single-dr.php

JDR Vol.18 No.1 pp. 21-26
(2023)
doi: 10.20965/jdr.2023.p0021

Note:

A Brief Questionnaire on Healthcare Workers’ Awareness Toward the COVID-19 Vaccine and Antibody Tests

Noriko Shimasaki*,†, Junko Ishii**, Tomoko Kuwahara*, and Haruna Nishijima*

*Department of Virology III, National Institute of Infectious Diseases
4-7-1 Gakuen, Musashimurayama, Tokyo 208-0011, Japan

Corresponding author

**Department of Neurology, Kobe City Medical Center General Hospital, Kobe, Japan

Received:
August 31, 2022
Accepted:
October 22, 2022
Published:
January 20, 2023
Keywords:
COVID-19, vaccine, antibody test, healthcare workers
Abstract

In 2022, the coronavirus disease 2019 (COVID-19) continues to spread worldwide with the emergence of many variants. Healthcare workers (HCWs) are encouraged to be vaccinated against COVID-19 because vaccines provide powerful protection from serious illnesses, hospitalization, and death. However, breakthrough infections on vaccinees have been frequently reported, and more studies are required to understand the mechanism of breakthrough infection and establish a standard neutralizing antibody (NTAb) level with efficacy. In particular, it is important to develop useful research tools for HCWs at high risk of breakthrough infection. Here, we administered a brief questionnaire on awareness of COVID-19 vaccines and antibody tests to uncover the needs of HCWs. Our questionnaire showed that HCWs felt a lower priority for vaccines among infection control measures than non-HCWs. On the other hand, HCWs expected more strongly the vaccine to be effective in preventing infection at work than non-HCWs. About half of the respondents, whether HCWs or not, thought that there was a correlation between the severity of adverse reactions and the degree of antibody induction. About 20% of the respondents had a change in awareness of the correlation after an antibody survey. Many respondents believed that the antibody test would be useful. Therefore, we should contribute to the development of a method of evaluating vaccines that can protect against infection and to improving other infection control measures in the future.

Cite this article as:
N. Shimasaki, J. Ishii, T. Kuwahara, and H. Nishijima, “A Brief Questionnaire on Healthcare Workers’ Awareness Toward the COVID-19 Vaccine and Antibody Tests,” J. Disaster Res., Vol.18, No.1, pp. 21-26, 2023.
Data files:
References
  1. [1] World Health Organization (WHO), “Weekly epidemiological update on COVID-19 - 10 August 2022,” Edition 104, 2022. https://www.who.int/publications/m/item/weekly-epidemiological-update-on-covid-19—10-august-2022 [Accessed August 20, 2022]
  2. [2] WHO, “COVID-19 advice for the public: Getting vaccinated (English version last updated on 13 April 2022),” 2022. https://www.who.int/emergencies/diseases/novel-coronavirus-2019/covid-19-vaccines/advice [Accessed July 25, 2022]
  3. [3] Ministry of Health, Labour and Welfare, “Vaccination of healthcare workers,” (in Japanese). https://www.mhlw.go.jp/stf/seisakunitsuite/bunya/vaccine_iryoujuujisha.html [Accessed July 25, 2022]
  4. [4] J. Jung, H. Sung, and S.-H. Kim, “COVID-19 breakthrough infections in vaccinated health care workers,” N. Engl. J. Med., Vol.385, pp. 1629-1631, 2021. https://doi.org/10.1056/NEJMc2113497
  5. [5] M. Klompas, “Understanding breakthrough infections following mRNA SARS-CoV-2 vaccination,” JAMA, Vol.326, No.20, pp. 2018-2020, 2021.
  6. [6] S. Stokes, K. Shek, and M. Hung, “Breakthroughs, boosters, and beyond: A practical primer on current challenges with COVID-19,” Emerg. Med. Pract., Vol.23, 22pp., 2021.
  7. [7] Y. Seki et al., “Safety and immunogenicity of the Pfizer/BioNTech SARS-CoV-2 mRNA third booster vaccine dose against the BA.1 and BA.2 Omicron variants,” Med, Vol.3, No.6, pp. 406-421.e4, 2022.
  8. [8] D. S. Khoury et al., “Neutralizing antibody levels are highly predictive of immune protection from symptomatic SARS-CoV-2 infection,” Nat. Med., Vol.27, No.7, pp. 1205-1211, 2021.
  9. [9] Ministry of Health, Labour and Welfare, “Diagnostic tests for COVID-19 infection,” (in Japanese). https://www.mhlw.go.jp/stf/seisakunitsuite/bunya/0000121431_00132.html#h2_free3 [Accessed August 27, 2022]
  10. [10] Japan Broadcasting Corporation (NHK), NHK coronavirus data. https://www3.nhk.or.jp/news/special/coronavirus/data/rules.html [Accessed August 27, 2022]
  11. [11] T. Takano et al., “Distinct immune cell dynamics correlate with the immunogenicity and reactogenicity of SARS-CoV-2 mRNA vaccine,” Cell Rep. Med., Vol.3, No.5, 100631, 2022.
  12. [12] N. Tani et al., “Relation of fever intensity and antipyretic use with specific antibody response after two doses of the BNT162b2 mRNA vaccine,” Vaccine, Vol.40, No.13, pp. 2062-2067, 2022.
  13. [13] Y. Kihara (Supervisor) and K. Kuroda (Ed.), “Infection control manual for COVID-19 of Kobe City Medical Center General Hospital,” MEDICUS SHUPPAN, Publishers Co., Ltd., 2021 (in Japanese).
  14. [14] N. Shimasaki and H. Morikawa, “Prevention of COVID-19 infection with personal protective equipment,” J. Disaster Res., Vol.16, No.1, pp. 61-69, 2021.
  15. [15] C. Higuchi et al., “Questionnaire survey on COVID-19 vaccination at Okayama University in Japan: Factors promoting vaccination among young adults,” J. Disaster Res., Vol.17, No.1, pp. 21-30, 2022.
  16. [16] H. Hasegawa, E. van Reit, and H. Kida, “Mucosal immunization and adjuvants,” M. B. A. Oldstone and R. W. Compans (Eds.), “Influenza pathogenesis and control – Volume II,” pp. 371-380, Springer, 2015.

*This site is desgined based on HTML5 and CSS3 for modern browsers, e.g. Chrome, Firefox, Safari, Edge, Opera.

Last updated on Feb. 01, 2023